mRNA Vaccine Core Enzyme Market to Reach USD 7 Billion by 2034

mRNA Vaccine Core Enzyme Market Overview 2025-2034
Luton, Bedfordshire, United Kingdom, June 16, 2025 (GLOBE NEWSWIRE) -- The global mRNA vaccine core enzyme market is witnessing unprecedented growth, driven by heightened demand for rapid vaccine development and growing advancements in biotechnology. As of 2024, the market is valued at approximately USD 2.3 billion, with projections indicating it will reach nearly USD 7 billion by 2034, reflecting a CAGR of 13.4% over the forecast period. This growth trajectory is underpinned by expanding applications of mRNA technology across infectious diseases, cancer therapeutics, and personalized medicine, along with increased public and private sector investments.
Download PDF Brochure: https://exactitudeconsultancy.com/request-sample/64421
The COVID-19 pandemic played a transformative role in bringing mRNA vaccine technologies into the spotlight, proving their potential for rapid response and scalable deployment. As governments, pharmaceutical companies, and research institutions pivot towards future pandemic preparedness and broader therapeutic applications, the core enzymes essential for mRNA synthesis and delivery—such as polymerases and lipid nanoparticles—are in increasingly high demand.
Market Segmentation Analysis
By Product Type
The market is segmented into Poly(A) Polymerase, RNA Polymerase, Nudge Enzyme, and Other Enzymes. Among these, Poly(A) Polymerase holds a dominant share due to its essential role in stabilizing synthetic mRNA transcripts for vaccine formulation. Enhanced purification techniques have also improved the quality and reliability of Poly(A) Polymerase, increasing its demand.
RNA Polymerase, equally critical, is widely used in transcription processes to synthesize mRNA from DNA templates. It finds applications in both commercial vaccine production and academic research. Nudge Enzymes, although newer to the market, are gaining traction due to their emerging role in improving mRNA stability and delivery efficiency. These innovations signal strong growth prospects, particularly for advanced research and personalized therapies.
By Application
The therapeutics segment is emerging as a key growth driver within the application spectrum, spurred by research into using mRNA technology for cancer treatment, autoimmune conditions, and rare diseases. Collaborations between biotech startups and large pharmaceutical firms are fostering the development of new therapeutic platforms leveraging mRNA enzymes.
In contrast, preventive vaccines remain the cornerstone of the mRNA enzyme market, bolstered by ongoing global vaccination programs and the anticipation of future pandemics. The success of COVID-19 mRNA vaccines has underscored the need for faster, adaptable vaccine platforms.
Research and development (R&D) also constitutes a significant market share. A surge in clinical trials and funding for pre-clinical mRNA studies—especially in academic and research institutions—continues to drive enzyme demand, particularly as R&D efforts expand to newer disease areas.
By End User
Pharmaceutical companies form the largest end-user segment, leveraging their production capacity, regulatory expertise, and global distribution networks to manufacture large volumes of mRNA-based products. These firms rely heavily on high-quality enzymes for consistent vaccine efficacy.
Academic and research institutions, while smaller in scale, play a vital role in early-stage innovation and pilot studies. They frequently collaborate with biotech firms to explore novel mRNA applications, thereby fueling demand for research-grade enzymes.
Biotech companies, particularly startups focused on gene editing and personalized medicine, represent a fast-growing end-user base. These companies require scalable and customizable enzyme solutions, thereby creating a niche yet dynamic demand profile.
By Technology
The market is further categorized by technology into In Vitro Transcription, Purification Technologies, and Quality Control and Characterization Technologies. Among these, In Vitro Transcription (IVT) is foundational to mRNA synthesis. Continued optimization has enhanced both yield and cost-efficiency, making IVT indispensable for vaccine production.
Purification technologies ensure removal of contaminants and increase product stability. Emerging trends involve automating these processes to minimize human error and improve throughput.
Meanwhile, quality control and characterization technologies are becoming increasingly vital due to stringent regulatory requirements. These technologies facilitate consistency, batch reproducibility, and compliance, making them a key area for future investments.
By Distribution Channel
Distribution of mRNA enzymes occurs through direct sales, online platforms, and third-party distributors. Direct sales remain preferred by pharmaceutical companies for custom orders and quality assurance, ensuring close coordination with enzyme manufacturers.
However, online sales are on the rise, particularly among academic institutions and smaller biotech firms looking for convenience and cost savings. The trend reflects a broader shift toward digital procurement models in the life sciences sector.
Third-party distributors serve an important role in extending enzyme availability to emerging markets and underserved regions. Their reach and logistical support are critical to ensuring timely supply in areas lacking direct access to manufacturers.
Browse full Report - https://exactitudeconsultancy.com/reports/64421/global-mrna-vaccine-core-enzyme-market
Market Segmentation
By Product Type - Poly(A) Polymerase - RNA Polymerase - Nudge Enzyme
By Application - Therapeutics - Preventive Vaccines - Research and Development
By End-user - Pharmaceutical Companies - Academic and Research Institutions - Biotech Companies
By Distribution Channel - Direct Sales - Online Sales - Third-party Distributors
By Technology - In Vitro Transcription - Purification technologies - Quality control and characterization technologies
By Region - North America - Europe - Asia Pacific - Latin America - Middle East and Africa
Regional Insights
North America
North America leads the global mRNA vaccine core enzyme market, contributing approximately 45% of global revenue in 2024. The U.S. stands at the forefront due to its robust biotech ecosystem, deep investment in R&D, and support from regulatory bodies like the FDA. Strategic collaborations between pharma giants and research institutions further accelerate innovation and commercialization. The region is expected to grow at a CAGR of around 8.5% through 2034.
Europe
Europe holds a significant market share of around 30%, led by countries like Germany, the UK, and France. Favorable government policies, strong academic research infrastructure, and a growing emphasis on biotechnology are propelling market growth. A CAGR of 7.0% is anticipated through 2034 as EU nations enhance their domestic vaccine capabilities and biotech investments.
Asia Pacific
Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 10.5% by 2034. Major drivers include rising investments in health infrastructure, expanding pharmaceutical manufacturing hubs in China and India, and increasing public health awareness. However, challenges such as regulatory complexity and uneven infrastructure persist across the region.
Latin America and Middle East & Africa
Emerging markets like Latin America and Africa are exhibiting strong growth potential, driven by improvements in public health funding and localized vaccine production. Though still nascent, these regions are expected to attract future investment. Infrastructure and regulatory challenges, however, may temper the pace of growth unless addressed through public-private collaboration.
Buy Now: https://exactitudeconsultancy.com/purchase/?currency=USD&type=single_user_license&report_id=64421
Key Competitors
Moderna Inc.
BioNTech SE
Pfizer Inc.
CureVac AG
Gennova Biopharmaceuticals
Zydus Cadila
Sanofi
AstraZeneca
Merck & Co., Inc.
Novavax Inc.
Regeneron Pharmaceuticals
Translate Bio
Genexine Inc.
AbCellera Biologics
Takeda Pharmaceutical Company Limited
Recent Market Developments
Moderna Inc. expanded its mRNA production facility in Norwood, Massachusetts in August 2023, aiming to scale up production in response to growing global demand.
BioNTech SE launched a next-generation mRNA-based influenza vaccine in September 2023, signaling a shift toward seasonal applications beyond COVID-19.
CureVac AG announced a strategic partnership in July 2023 with a major pharmaceutical firm to co-develop mRNA therapies, highlighting a trend toward collaboration and shared risk.
Zydus Cadila received regulatory approval in India for its mRNA COVID-19 vaccine in October 2023, positioning the country as a significant player in localized mRNA production.
Pfizer Inc. acquired a biotech firm specializing in advanced mRNA platforms in November 2023, bolstering its pipeline and reaffirming its commitment to innovation.
This report is also available in the following languages : Japanese (mRNAワクチンコア酵素市場), Korean (mRNA 백신 핵심 효소 시장), Chinese (mRNA疫苗核心酶市场), French (Marché des enzymes de base des vaccins à ARNm), German (Markt für mRNA-Impfstoff-Kernenzyme), and Italian (Mercato degli enzimi fondamentali del vaccino mRNA), etc.
Request Sample Pages: https://exactitudeconsultancy.com/reports/64421/global-mrna-vaccine-core-enzyme-market#request-a-sample
More Research Finding –
Tozinameran Market
The global market for Tozinameran, a key COVID-19 mRNA vaccine, is valued at approximately $21 billion. The market is expected to grow significantly, with a projected value of around $45 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of about 8.1% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/66480/tozinameran-market
mRNA Vaccine and Therapeutics Raw Material Market
The global market for mRNA vaccine and therapeutics raw materials is valued at approximately $4.5 billion, driven by the accelerating demand for innovative vaccine solutions and therapeutic modalities. The market is projected to reach around $9.2 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of approximately 8.2% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65932/mrna-vaccine-and-therapeutics-raw-material-market
Non-invasive Vaccine Market
The global non-invasive vaccine market is projected to reach a value of approximately $2.5 billion in 2024, driven by advancements in vaccine delivery systems and increasing demand for pain-free immunization methods. During the forecast period from 2025 to 2034, the market is expected to experience significant growth, with an estimated compound annual growth rate (CAGR) of 11.5%.
https://exactitudeconsultancy.com/reports/59766/global-non-invasive-vaccine-market
Foot and Mouth Disease FMD Vaccines for Pig Market
The global market for Foot and Mouth Disease (FMD) vaccines for pigs is projected to reach approximately $1.2 billion in 2024, with a significant growth trajectory anticipated through the next decade. By 2034, the market value is expected to rise to about $2.3 billion, reflecting a robust Compound Annual Growth Rate (CAGR) of 6.9% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/59747/global-foot-and-mouth-disease-fmd-vaccines-for-pig-market
Flu RNA Vaccines Market
The global market for flu RNA vaccines is valued at approximately $2.5 billion, reflecting a growing demand for innovative vaccination solutions amid rising flu cases and the ongoing need for enhanced public health measures. Projections indicate that the market will expand to around $6 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 9.1% over the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/55918/global-flu-rna-vaccines-market
Pediatric Vaccines Market
The global pediatric vaccines market is valued at approximately $40 billion, driven by increasing immunization rates and the growing incidence of infectious diseases among children. With advancements in vaccine technologies and rising awareness of preventive healthcare, the market is projected to reach around $70 billion by 2034, marking substantial growth.
https://exactitudeconsultancy.com/reports/52011/pediatric-vaccines-market
Shingles Vaccine Market
The global shingles vaccine market is valued at approximately $5.1 billion, driven by increasing awareness of shingles and rising vaccination rates among older populations. The market is projected to grow significantly, reaching an estimated value of $10 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 7.1% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/51861/shingles-vaccine-market
U.S. Meningococcal Vaccines Market
The U.S. meningococcal vaccines market is valued at approximately $1.5 billion, reflecting a robust demand driven by increasing awareness of meningococcal disease and vaccination initiatives. The market is projected to grow at a CAGR of 6.2%, reaching an estimated $2.7 billion by 2034. This growth trajectory is propelled by several factors, including expanded recommendations for vaccination among adolescents and young adults, and the ongoing efforts to enhance vaccine accessibility and education.
https://exactitudeconsultancy.com/reports/50804/u-s-meningococcal-vaccines-market
Rna Based Therapeutics Market
The RNA-based therapeutics market is projected to reach a value of approximately $7.3 billion in 2024, driven by advancements in mRNA technology and increasing investments in gene therapies. The market is expected to expand significantly with a projected value of around $19.6 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 10.4% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/50749/rna-based-therapeutics-market
U.S. Vaccine Technologies Market
The U.S. vaccine technology market is valued at approximately $70 billion, buoyed by increasing demand for innovative vaccines and heightened awareness of public health needs. The market is projected to grow significantly, with an estimated value reaching $110 billion by 2034, reflecting a robust growth trajectory.
https://exactitudeconsultancy.com/reports/50446/u-s-vaccine-technologies-market
Chikungunya Vaccine Future Trends and Market
The global chikungunya vaccine market is projected to hold a value of approximately $2.5 billion in 2024. Given the increasing incidence of chikungunya virus infections and the growing awareness regarding preventative healthcare measures, the market is expected to reach around $5.6 billion by 2034. This outlook suggests a robust Compound Annual Growth Rate (CAGR) of 8.5% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/50225/chikungunya-vaccine-market
Innovations in Vaccine Technologies Market
The global vaccine technologies market is projected to reach a value of approximately $65 billion in 2024, with expectations to grow to about $110 billion by 2034. This trajectory represents a compound annual growth rate (CAGR) of around 5.3% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/50217/vaccine-technologies-market
Dendritic Cell Therapy Vaccine Market
The dendritic cell therapy vaccine market is valued at approximately $1.2 billion, reflecting a robust interest in innovative immunotherapy solutions. The market is projected to reach around $3.4 billion by 2034, indicating a substantial growth trajectory driven by advancements in personalized medicine and an increasing prevalence of cancer worldwide.
https://exactitudeconsultancy.com/reports/66582/dendritic-cell-therapy-vaccine-market
Gammaretroviral Vector Market
The gammaretroviral vector market is anticipated to reach approximately $1.2 billion in 2024, driven by advancements in gene therapies and increasing applications in biomedical research. The market is projected to grow significantly, with an estimated compound annual growth rate (CAGR) of 8.5% from 2025 to 2034, ultimately reaching around $2.7 billion by the end of this forecast period.
https://exactitudeconsultancy.com/reports/66577/gammaretroviral-vector-market
Multi Use Bioreactor Market
The global multi-use bioreactor market is valued at approximately $3.2 billion, reflecting significant growth driven by advances in biopharmaceutical manufacturing and increased demand for personalized medicine. The projected market value for 2025-2034 is estimated to reach $6.5 billion, highlighting the sector's robust expansion.
https://exactitudeconsultancy.com/reports/66574/multi-use-bioreactor-market
Medical Refrigerated Market
The global medical refrigerated market is valued at approximately $6.5 billion in 2024, with projections indicating a potential increase to around $10 billion by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of approximately 4.5% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/66520/medical-refrigerated-market
Needle for Disposable Injection Pen Market
The disposable injection pen market is valued at approximately $4.5 billion in 2024, with expectations to grow significantly over the next decade, reaching an estimated $9 billion by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of around 7.5% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/66462/needle-for-disposable-injection-pen-market
Meningitis B Vaccine Market
The global market for Meningitis B vaccines is valued at approximately $1.1 billion. Projections indicate robust growth, with the market expected to reach $2.4 billion by 2034, driven by increasing awareness of preventive healthcare and advancements in vaccine technology. This represents a Compound Annual Growth Rate (CAGR) of around 8.2% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65956/meningitis-b-vaccine-market
Human Papillomavirus Vaccine Types 16 18 Market
The global market for Human Papillomavirus (HPV) vaccines, particularly those aimed at preventing types 16 and 18, is valued at approximately $3 billion. The market is projected to reach around $5 billion by 2034, reflecting heightened awareness of HPV-related health risks and increased vaccination initiatives worldwide.
https://exactitudeconsultancy.com/reports/65955/human-papillomavirus-vaccine-types-16-18-market
CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@exactitudeconsultancy.comSign in to access your portfolio

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Upturn

43 minutes ago

• Business Upturn

Key Home Goods Unveils Limited Edition Cutting Board Collection: Where Functional Art Meets Heritage Craftsmanship

DALLAS, June 21, 2025 (GLOBE NEWSWIRE) — Key Home Goods , a design-forward brand rooted in old-world craftsmanship and modern heritage, proudly announces the release of its Signature Collection, a limited-edition series of artisan-crafted end-grain cutting boards and designer charcuterie boards that merge timeless form with everyday function. Key Home Goods Signature Collection houndstooth cutting board. Each piece in the collection is meticulously handcrafted from American hardwoods, finished with a blend of food-safe oils and waxes, and showcases the brand's distinctive proprietary houndstooth patterns, a visual hallmark that has become synonymous with Key Home Goods. With production strictly limited, every board is reserved for those who seek beauty, exclusivity, and purpose in all that they do. At the heart of this launch is Andrew Key, a seventh-generation Texan, fine woodworker, and the founder of Key Home Goods. What began in 2019 as a pair of custom end-grain cutting boards made as wedding gifts for lifelong friends has grown into a full-fledged pursuit of heirloom craftsmanship. 'I never set out to start just another cutting board company,' says Andrew. 'I wanted to create something truly extraordinary, pieces to be cherished, passed down, and appreciated for both their function and elegance.' The Signature Collection represents more than kitchen tools; it's functional art, thoughtfully designed to elevate the rituals of cooking and gathering. Each board is book-matched for visual harmony, then assembled into a composition that's as structurally resilient as it is visually stunning, honoring the heritage of end-grain cutting boards while pioneering new ground in their design. 'Every board is made slowly, with intention,' Andrew explains. 'Owning a Key Home Goods board is an invitation to savor life's richest moments. A centerpiece for gatherings and a canvas for creating memories with those you love. No two are alike, but every one is designed to be the best board you'll ever own, and the last one you'll ever need.' The Signature Collection is available exclusively at , with early access to new releases offered to registered collectors. Each board ships in custom packaging and includes access to the brand's white-glove support and timeless warranty, known as the Timeless Guarantee. Media Contact:Andrew KeyKey Home Goods [email protected]

Business Upturn

44 minutes ago

• Business Upturn

New Subsidiary in Mexico: SOUEAST Debuts S06 i-DM, S07, S09, Pushes Advanced New Energy Tech

By GlobeNewswire Published on June 22, 2025, 09:11 IST MEXICO CITY, June 22, 2025 (GLOBE NEWSWIRE) — On June 18, 2025, at the grand brand and products launch ceremony in Centro Citibanamex, Mexico, SOUEAST announced its entry to Mexican market and unveiled three new models, attracting wide attention, signaling a significant breakthrough in SOUEAST's Latin American expansion. SOUEAST, true to the 'EASE YOUR LIFE' philosophy, is dedicated to urban mobility with stylish, comfort, and warm-tech at its core. SOUEAST offers a diverse range of models — including SUVs and sedans — specifically designed for urban youth. (Image 1: SOUEAST Brand Launch in Mexico) Three Prominent Models Debut: Meeting Diverse Mobility NeedsAt this launch ceremony, SOUEAST introduced three urban-focused models with both fuel and hybrid power types as follows: The S06 i-DM, an urban stylish C-class hybrid SUV, focuses on sporty aesthetics and high efficiency. With its hybrid capabilities and outstanding range, its head-turning contemporary design houses advanced hybrid technology, delivering an impressive 114 km pure electric range and a combined range of over 1,000 km when fully fueled, fully meeting the diverse needs of young people for daily commuting and urban traffic congestion in Mexico. It enhances the driving experience with intelligent features including L2 autonomous driving capabilities and comprehensive smart safety systems. (Image 2: SOUEAST S06 i-DM) The S07, an urban intelligent C-class SUV, skillfully combines practicality and style for urban trendy and fun-loving youth. Beyond its stylish design and comfortable interior, it delivers intelligent features including dual 12.3-inch screens, 6-way adjustable driver seat with memory, remote start and full ADAS, offering luxury-grade connectivity and safety. The S09, a flagship smart premium D-class SUV, redefines spacious luxury with its commanding 4,858*1,925*1,780mm dimensions and 2,850mm wheelbase. Its 7-seat version catering specifically to multi-passenger needs. Powered by a robust 2.0T engine, it caters to urban users with its aesthetic design, intelligent driving, and luxurious features, embodying the brand's high standards. (Image 3: SOUEAST S07 and S09) Each model in the lineup embodies SOUEAST's 'STYLISH-COMFORT-WARM TECH' product DNA, seamlessly integrating innovative technology and exceptional quality, to meet diverse urban mobility needs with EASE. Promoting Comprehensive Localized Operations Regarding the long-term development plan for the Mexican market, SOUEAST adheres to the concept of 'In Mexico, For Mexico' and promotes a comprehensive localized business strategy. In terms of network construction, the company plans to establish 40 showrooms by the end of 2025 and expand to 50 in 2026 in Mexico, building a convenient and efficient service network through a standardized service system. On the after-sales front, preparations are underway for a regional spare parts center for Latin America. This facility will ensure 100% parts availability and enable 24-hour delivery, ensuring rapid response to customer service needs. Meanwhile, the company actively promotes the establishment of the Central and South American Research Institute. Centered on localized product development, the institute aims to introduce models that are better aligned with the preferences and needs of Mexico customers. Driving a New Journey in Latin America: Leading the Future of Green Mobility The Mexican subsidiary showcase SOUEAST's firm commitment to the Latin American market, bringing advanced new energy vehicle(NEV) technologies to Mexico. By offering smart, eco-friendly, and diverse mobility solutions for urban youth, SOUEAST is accelerating Mexico's green transition while expanding its global footprint, with plans to introduce more NEV models and reinforce its role in sustainable development worldwide. Since initiating its globalization strategy in 2024, SOUEAST has made continuous strides across key international markets. Following its global debut in Uzbekistan and rapid entry into multiple markets across the Middle East, the successful launch in Mexico marks another milestone in its growing global presence. To date, SOUEAST has entered more than 30 countries and regions, with over 144 sales and service outlets. Looking ahead, the brand aims to expand into more than 80 markets and establish over 2,000 outlets within five years—bringing the EASE Urban Lifestyle to users worldwide. Photos accompanying this announcement are available at: Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

New York Times

an hour ago

• New York Times

‘I Feel Like I've Been Lied To': When a Measles Outbreak Hits Home

He was a chiropractor by training, but in a remote part of West Texas with limited medical care, Kiley Timmons had become a first stop for whatever hurt. Ear infections. Labor pains. Oil workers who arrived with broken ribs and farmers with bulging discs. For more than a decade, Kiley, 48, had seen 20 patients each day at his small clinic located between a church and a gas station in Brownfield, population 8,500. He treated what he could, referred others to physicians and prayed over the rest. It wasn't until early this spring that he started to notice something unfamiliar coming through the door: aches that lingered, fevers that wouldn't break, discolored patches of skin that didn't make sense. At first, he blamed it on a bad flu season, but the symptoms stuck around and then multiplied. By late March, a third of his patients were telling him about relatives who couldn't breathe. And then Kiley started coughing, too. His wife, Carrollyn, had recently tested positive for Covid, but her symptoms eased as Kiley's intensified. He went to a doctor at the beginning of April for a viral panel, but every result came back negative. The doctor decided to test for the remote possibility of measles, since there was a large outbreak spreading through a Mennonite community 40 miles away, but Kiley was vaccinated. 'I feel like I'm dying,' Kiley texted a friend. He couldn't hold down food or water. He had already lost 10 pounds. His chest went numb, and his arms began to tingle. His oxygen was dropping dangerously low when he finally got the results. 'Positive for measles,' he wrote to his sister, in mid-April. 'Just miserable. I can't believe this.' Twenty-five years after measles was officially declared eliminated from the United States, this spring marked a harrowing time of rediscovery. A cluster of cases that began at a Mennonite church in West Texas expanded into one of the largest outbreaks in a generation, spreading through communities with declining vaccination rates as three people died and dozens more were hospitalized from Mexico to North Dakota. Public health officials tracked about 1,200 confirmed cases and countless exposures across more than 30 states. People who were contagious with measles boarded domestic flights, shopped at Walmart, played tuba in a town parade and toured the Mall of America. Want all of The Times? Subscribe.